MEK/BRAF Inhibition May Overcome Molecular Heterogeneity of BRAF-Mutant Melanoma

Deeper inhibition of the MAPK pathway by targeting both MEK and BRAF may help improve progression-free survival outcomes in patients with advanced BRAF V600 –mutated melanoma.

Source: CancerNetwork - May 25, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Melanoma SiteTerms/www.cannabissciencetech.com/News Source Type: news